Rigel Pharmaceuticals, Inc. Q4 FY2025 earnings call

Raul Rodriguez outlined Rigel's transformational growth strategy in hematology and oncology with four core objectives: grow commercial business, expand portfolio via in-licensing/acquisition, advance clinical development pipeline, and maintain financial discipline. Over the last five years, Rigel transformed from a single product company to having three commercial products with approved indications. The development pipeline is led by R289, a dual IRAC1 and 4 inhibitor. Dave Santos discussed commercial product growth, with net sales consistently growing over the last five years. Lisa Royker provided an update on the development pipeline, including progress on R289 Phase 1b study and collaborations for elutacidinib. Dean Shornow discussed financials, including fourth quarter and full year 2025 results and 2026 financial outlook.

In the fourth quarter of 2025, Tavalise generated $45.6 million in net product sales, a 47% increase compared to the fourth quarter of 2024. Gavretto had $10.2 million in net product sales, a 27% increase y-o-y. ResLydia reported $9.6 million in net product sales, a 29% increase from the prior year period. For the full year 2025, net product sales were $232 million, an $87 million (60%) increase compared to 2024. The growth was driven by increased demand across the portfolio, including a one-time favorable effect from increased patient affordability and favorable gross to net dynamics, partially offset by lower inventory levels.

Rigel expects total revenue in 2026 to be in the range of approximately $275 to $290 million, comprised of approximately $255 to $265 million in net product sales and $20 to $25 million of contract revenues. The company anticipates reporting positive net income for the full year while funding existing and new clinical development programs.

The call mentioned that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted, as described in the most recent annual report on Form 10-K filed with the SEC.

Q: For Tavalise, what are the incremental growth drivers since it's a relatively mature product and about Guerrero's potential growth?

A: Dave Santos mentioned Tavalise's growth was helped by a one-time favorable effect from increased patient affordability (elimination of coverage gap for Medicare Part D patients) and focus on growing new patient starts through spreading the message. For Gavretto, it was a stable contributing product with growth from being available for a full year in 2025 compared to half a year in 2024, and continuing targeted efforts to grow.

Q: On R289 dosing, pros and cons and BD progress?

A: Raul Rodriguez said they compared 500 mg daily and 500 mg BID for dose expansion, waiting to see data on which may be more effective. On BD, Rigel is evaluating late-stage opportunities in hematology/oncology that are NDA-ready or approved, looking to add value to product launches and hoping to close a deal in 2026.

Q: Strategic rationale for exploring post-ESA or treatment-naive MDS with R289?

A: Lisa Royker said R289 started in heavily pretreated, high transfusion burden patients and they're optimistic activity may be better in earlier lines as currently approved products have limitations.

Q: Enrollment in R289 dose expansion phase and net sales guidance conservativeness?

A: Farzeen Hakiu was told enrollment in dose expansion is progressing, aiming to select recommended phase two dose in second half of 2026. Dave Santos said 2025 growth was driven by strong demand and one-time affordability effect, 2026 guidance is double-digit growth off a higher base without the one-time effect but still high expectations.

Q: Plans for sales force given revenue growth?

A: Dave Santos said they focus sales force on areas with most opportunity, are right-sized, and look to be more impactful with existing resources rather than expanding the sales organization currently